Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lo.Li.Pharma s.r.l
The present study aims to evaluate the possible beneficial effect of a treatment with Inofolic HP combined with Inofolic phD on the improvement if menstrual cycle alteration in adolescent patients with or without PCOS.
The molecules chosen for the study are the following: myo-Inositol, α-lactalbumin, Dioscorea Villosa, and Vitamin D, are already commercialized as dietary supplements, commonly administered at same dosage provided in the present study, also for prolonged treatments, with no side effects associated.
Age
14–19
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
adolescent women aged 14-19 years old, with at least 3 years passed after menarche, and oligomenorrhea or amenorrhea
You may not be if
Primary amenorrhea.
Hyperandrogenism due to other factors (i.e. adrenal hyperplasia or Cushing syndrome).
Hyperprolactinemia or overt hypothyroidism (TSH ≥4).
Other hormonal alterations.
Ongoing hormonal therapies, including OCPs, six months before enrollment.
Ongoing pharmacological therapies.
Ongoing use of myo-Inositol supplement or other source of myo-Inositol, or Dioscorea villosa, six months before enrollment.